OpGen Entered Into An Agreement To Sell Its Commercial Customer Contracts And Installed Base Of Unyvero Systems To Camtech Pte Ltd For $218,000
Portfolio Pulse from Benzinga Newsdesk
OpGen, Inc. (NASDAQ:OPGN) has agreed to sell its Unyvero systems and commercial customer contracts to Camtech Pte Ltd for $218,000, following Camtech's acquisition of Curetis' Unyvero assets. Additionally, OpGen's subsidiary Ares Genetics sold its assets to bioMerieux S.A. as part of insolvency proceedings. OpGen is preparing for a potential strategic transaction, including a reverse merger, to benefit stockholders.
April 29, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OpGen sells Unyvero systems and contracts to Camtech for $218,000 and is preparing for a potential strategic transaction to benefit stockholders.
The sale of Unyvero systems and contracts to Camtech, along with the potential for a strategic transaction such as a reverse merger, indicates a strategic shift for OpGen that could lead to future value growth for stockholders. This news is likely to be viewed positively by investors as it shows management's proactive steps towards restructuring and potentially enhancing shareholder value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100